Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting glutamine metabolism in myeloproliferative neoplasms.

Blood cells, molecules & diseases - 1 Oct 2015

Zhan Huichun, Ciano Kristen, Dong Katherine, Zucker Stanley

Abstract excerpt

JAK2(V617F) mutation can be detected in the majority of myeloproliferative neoplasm (MPN) patients. The JAK2 inhibitor Ruxolitinib is the first FDA-approved treatment for MPNs. However, its use is limited by various dose related toxicities. Here, we studied the metabolic state and glutamine metabolism of BaF3-hEPOR-JAK2V617F and BaF3-hEPOR-JAK2WT cells. We found that the JAK2(V617F)-mutant cells were associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Glutamine
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Disorders

Share to Nitriles

Share to Pyrazoles

Share to Pyrimidines

Share to Up-Regulation

Source

Open in PubMed Open full text

Identifiers

PMID: 26227854
DOI: 10.1016/j.bcmd.2015.07.007
PMCID: PMC5105231

Genes

JAK2
GLS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting glutamine metabolism in myeloproliferative neoplasms.PMID 26227854Read ↗

The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN.Semantic proximity Read ↗

Glutamine addiction is a therapeutic target to block emergency myelopoiesisSemantic proximity Read ↗

Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.Semantic proximity Read ↗

Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.Semantic proximity Read ↗

Targeting Amino Acid Metabolic Vulnerabilities in Myeloid MalignanciesSemantic proximity Read ↗

A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancerSemantic proximity Read ↗

Acute Myeloid Leukaemia Drives Metabolic Changes in the Bone Marrow NicheSemantic proximity Read ↗

The Glycolytic Gatekeeper PDK1 defines different metabolic states between genetically distinct subtypes of human acute myeloid leukemia.Semantic proximity Read ↗

Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.Semantic proximity Read ↗

Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis.Semantic proximity Read ↗

Role and therapeutic targeting of glutamine metabolism in non‑small cell lung cancer (Review)Semantic proximity Read ↗

Advances in Understanding of Metabolism of B-Cell Lymphoma: Implications for TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.